|
Volumn 13, Issue 4, 1999, Pages 195-200
|
The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia
|
Author keywords
Acute promyelocytic leukemia; Arsenic trioxide treatment; Mechanisms of biological effects
|
Indexed keywords
ANTINEOPLASTIC AGENT;
ARSENIC;
ARSENIC TRIOXIDE;
RETINOIC ACID;
ORGANOARSENIC DERIVATIVE;
OXIDE;
ACUTE MYELOBLASTIC LEUKEMIA;
ADULT;
APOPTOSIS;
AREA UNDER THE CURVE;
CELL CYCLE;
CELL DIFFERENTIATION;
CELL KILLING;
CELL PROLIFERATION;
CHILD;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG MECHANISM;
ENZYME ACTIVITY;
GENE EXPRESSION REGULATION;
HUMAN;
HUMAN CELL;
LEUKEMIA CELL;
MAJOR CLINICAL STUDY;
MITOSIS INHIBITION;
REVIEW;
CELL DIVISION;
CELL STRAIN HL 60;
DOSE RESPONSE;
DRUG EFFECT;
PATHOLOGY;
PROMYELOCYTIC LEUKEMIA;
RANDOMIZED CONTROLLED TRIAL;
REMISSION;
TISSUE DISTRIBUTION;
TREATMENT OUTCOME;
ADULT;
ANTINEOPLASTIC AGENTS;
APOPTOSIS;
ARSENICALS;
CELL DIFFERENTIATION;
CELL DIVISION;
CHILD;
DOSE-RESPONSE RELATIONSHIP, DRUG;
GENE EXPRESSION REGULATION, LEUKEMIC;
HL-60 CELLS;
HUMANS;
LEUKEMIA, PROMYELOCYTIC, ACUTE;
OXIDES;
RANDOMIZED CONTROLLED TRIALS;
REMISSION INDUCTION;
TISSUE DISTRIBUTION;
TREATMENT OUTCOME;
TRETINOIN;
|
EID: 0033233291
PISSN: 0393974X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (42)
|
References (60)
|